These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 14619277)

  • 1. The cost effectiveness of pharmacotherapies for smoking cessation: necessary but not sufficient?
    Shanahan M; Doran C; Gates J; Shakeshaft A; Mattick RP
    Appl Health Econ Health Policy; 2003; 2(2):76-8. PubMed ID: 14619277
    [No Abstract]   [Full Text] [Related]  

  • 2. A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
    Hill A
    Tex Med; 2006 Aug; 102(8):50-5. PubMed ID: 17115560
    [No Abstract]   [Full Text] [Related]  

  • 3. Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05.
    Lutsenko H; Doran CM; Hall WD
    Drug Alcohol Rev; 2008 Mar; 27(2):160-4. PubMed ID: 18264876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation.
    Nielsen K; Fiore MC
    Prev Med; 2000 Mar; 30(3):209-16. PubMed ID: 10684744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefits of switching smoking cessation drugs to over-the-counter status.
    Keeler TE; Hu TW; Keith A; Manning R; Marciniak MD; Ong M; Sung HY
    Health Econ; 2002 Jul; 11(5):389-402. PubMed ID: 12112489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National trends in the provision of smoking cessation aids within the Veterans Health Administration.
    Jonk YC; Sherman SE; Fu SS; Hamlett-Berry KW; Geraci MC; Joseph AM
    Am J Manag Care; 2005 Feb; 11(2):77-85. PubMed ID: 15726855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Methods and cost effectiveness of nicotine abstinence].
    Górecka D
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():79-82. PubMed ID: 15524024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.
    Cornuz J; Gilbert A; Pinget C; McDonald P; Slama K; Salto E; Paccaud F
    Tob Control; 2006 Jun; 15(3):152-9. PubMed ID: 16728744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
    Bertram MY; Lim SS; Wallace AL; Vos T
    Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The place of pharmacotherapy products in smoking cessation.
    Percival J
    Prof Nurse; 2003 Oct; 19(2):113-7. PubMed ID: 14593787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should smoking cessation cost a packet? A pilot randomized controlled trial of the cost-effectiveness of distributing nicotine therapy free of charge.
    Dey P; Foy R; Woodman M; Fullard B; Gibbs A
    Br J Gen Pract; 1999 Feb; 49(439):127-8. PubMed ID: 10326267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
    Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
    Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of varenicline for smoking cessation.
    Keiding H
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Can the society afford not to subsidize smoking cessation?].
    Larsson M; Larsson K; Gilljam H; Curman B
    Lakartidningen; 2002 Jun; 99(23):2665-6. PubMed ID: 12101625
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of transdermal nicotine patches for nicotine replacement and smoking cessation.
    Holdcroft C
    Nurse Pract; 1992 Jul; 17(7):46-8. PubMed ID: 1495597
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
    Song F; Raftery J; Aveyard P; Hyde C; Barton P; Woolacott N
    Med Decis Making; 2002; 22(5 Suppl):S26-37. PubMed ID: 12369228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration.
    Rauhut AS; Dwoskin LP; Bardo MT
    Nicotine Tob Res; 2005 Dec; 7(6):901-7. PubMed ID: 16298725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands.
    Vemer P; Rutten-van Mölken MP; Kaper J; Hoogenveen RT; van Schayck CP; Feenstra TL
    Addiction; 2010 Jun; 105(6):1088-97. PubMed ID: 20659063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness of the methods of smoking cessation].
    Plans P; Navas E; Tarín A; Rodríguez G; Galí N; Gayta R; Taberner JL; Salleras L
    Med Clin (Barc); 1995 Jan; 104(2):49-54. PubMed ID: 7869779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of the nicotine patch.
    Stevermer J
    J Fam Pract; 1996 Aug; 43(2):125-6. PubMed ID: 8708620
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.